Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis.

PURPOSE Many anticancer therapies exert their therapeutic effect by inducing apoptosis in target tumors. We evaluated in a Phase I study the safety and the feasibility of (99m)Tc-Annexin V for imaging chemotherapy-induced apoptosis in human cancers immediately after the first course of chemotherapy. EXPERIMENTAL DESIGN Fifteen patients presenting with lung cancer (n = 10), lymphoma (n = 3), or breast cancer (n = 2) underwent (99m)Tc-Annexin V scintigraphy before and within 3 days after their first course of chemotherapy. Tumor response was evaluated by computed tomography and (18)F-fluoro-2-deoxy-D-glucose positron emission tomography scans, 3 months in average after completing the treatment. Median follow-up was 117 days. RESULTS In all cases, no tracer uptake was observed before treatment. However, 24-48 h after the first course of chemotherapy, 7 patients who showed (99m)Tc-Annexin V uptake at tumor sites, suggesting apoptosis, had a complete (n = 4) or a partial response (n = 3). Conversely, 6 of the 8 patients who showed no significant posttreatment tumor uptake had a progressive disease. Despite the lack of tracer uptake after treatment, the 2 patients with breast cancer had a partial response. Overall survival and progression-free survival were significantly related to tracer uptake in treated lung cancers and lymphomas (P < 0.05). No serious adverse events were observed. CONCLUSIONS Our preliminary results demonstrated the feasibility and the safety of (99m)Tc-Annexin V for imaging apoptosis in human tumors after the first course of chemotherapy. Initial data suggest that early (99m)Tc-Annexin V tumor uptake may be a predictor of response to treatment in-patients with late stage lung cancer and lymphoma.

[1]  David L. Vaux,et al.  Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells , 1988, Nature.

[2]  Z. Darżynkiewicz.  Apoptosis in anititumor strategies: Modulation of cell cycle or differentiation , 1995, Journal of cellular biochemistry.

[3]  F. Blankenberg,et al.  Imaging cyclophosphamide-induced intramedullary apoptosis in rats using 99mTc-radiolabeled annexin V. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  J. Hickman,et al.  Apoptosis induced by anticancer drugs , 1992, Cancer and Metastasis Reviews.

[5]  D Delbeke,et al.  Oncological applications of FDG PET imaging. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  J. Crocker,et al.  Apoptosis in squamous cell carcinoma of the lung: correlation with survival and clinicopathological features , 2001, Journal of clinical pathology.

[7]  D. Agrawal,et al.  Morphological and biochemical characterization and analysis of apoptosis. , 1997, Journal of pharmacological and toxicological methods.

[8]  F. Blankenberg,et al.  Apoptosis: The importance of nuclear medicine , 2000, Nuclear medicine communications.

[9]  P. Doevendans,et al.  Visualisation of cell death in vivo in patients with acute myocardial infarction , 2000, The Lancet.

[10]  S. Hirohashi,et al.  Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas. , 1991, Cancer research.

[11]  J. Freyssinet,et al.  Formation of two-dimensional arrays of annexin V on phosphatidylserine-containing liposomes. , 1994, Journal of molecular biology.

[12]  G. Berry,et al.  Radionuclide imaging of acute lung transplant rejection with annexin V. , 2000, Chest.

[13]  V. R. McCready,et al.  FDG accumulation and tumor biology. , 1998, Nuclear medicine and biology.

[14]  S. Lowe,et al.  Apoptosis in cancer. , 2000, Carcinogenesis.

[15]  F. Blankenberg,et al.  Technetium-99m HYNIC-annexin V: a potential radiopharmaceutical for the in-vivo detection of apoptosis , 1999, European Journal of Nuclear Medicine.

[16]  J. Martínez,et al.  Microvessel density, p53 overexpression, and apoptosis in invasive breast carcinoma. , 1997, Molecular pathology : MP.

[17]  A. Schroit,et al.  Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. , 1997, Blood.

[18]  J. Fitzner,et al.  Development and biologic evaluation of a kit for preformed chelate technetium-99m radiolabeling of an antibody Fab fragment using a diamide dimercaptide chelating agent. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[19]  F. Blankenberg,et al.  Annexin-V imaging for noninvasive detection of cardiac allograft rejection , 2001, Nature Medicine.

[20]  A. Wyllie,et al.  Apoptosis: A Basic Biological Phenomenon with Wide-ranging Implications in Tissue Kinetics , 1972, British Journal of Cancer.

[21]  A. Whetton,et al.  Induction of apoptosis--new targets for cancer chemotherapy. , 1992, Seminars in cancer biology.

[22]  R. Huber,et al.  Crystal and molecular structure of human annexin V after refinement. Implications for structure, membrane binding and ion channel formation of the annexin family of proteins. , 1992, Journal of molecular biology.

[23]  S. Lowe,et al.  Cancer therapy and p53. , 1995, Current opinion in oncology.

[24]  M D Blaufox,et al.  PET imaging in oncology. , 2000, Seminars in nuclear medicine.

[25]  F. Blankenberg,et al.  99mTc Annexin V Imaging of Neonatal Hypoxic Brain Injury , 2000, Stroke.

[26]  R. Davis,et al.  Imaging of apoptosis (programmed cell death) with 99mTc annexin V. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  D. Green,et al.  Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl , 1995, The Journal of experimental medicine.

[28]  A. Demidem,et al.  Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. , 1997, Cancer biotherapy & radiopharmaceuticals.

[29]  J. Tait,et al.  Organization of the human annexin V (ANX5) gene. , 1994, Genomics.

[30]  F. Blankenberg,et al.  Radiolabeled annexin V imaging: diagnosis of allograft rejection in an experimental rodent model of liver transplantation. , 2000, Radiology.

[31]  G. Evan,et al.  Oncogenes and cell death. , 1994, Current opinion in genetics & development.

[32]  O. Warburg.  On the origin of cancer cells. , 1956, Science.

[33]  G. Evan,et al.  Proliferation, cell cycle and apoptosis in cancer , 2001, Nature.

[34]  H. Ellis.  stroke , 1997, The Lancet.

[35]  Seamus J. Martin,et al.  Dose‐dependent induction of apoptosis in human tumour cell lines by widely diverging stimuli , 1991, Cell proliferation.

[36]  G. Berry,et al.  The use of technetium Tc 99m annexin V for in vivo imaging of apoptosis during cardiac allograft rejection. , 1998, The Journal of thoracic and cardiovascular surgery.

[37]  P. Meers,et al.  Relationship between annexin V tryptophan exposure, calcium, and phospholipid binding. , 1993, Biochemistry.

[38]  R. Warnke,et al.  Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. , 1987, The New England journal of medicine.